alexa
Reach Us +443308085114
Clinical Development Of Biosimilars For Western Markets: Planning For Success | 70771
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Clinical development of biosimilars for Western markets: Planning for success

8th Asian Biologics and Biosimilars Congress

Charu Manaktala

Quintiles IMS, India

Keynote: J Bioanal Biomed

DOI: 10.4172/1948-593X-C1-031

Abstract
Clinical development of biosimilars is an expensive and time consuming undertaking. The biosimilars space continues to evolve rapidly and presents a number of unique challenges and fierce competition. There are as many as 20 biosimilars in development for some of the top-selling biologicals creating an intense race for the sponsors, especially those wishing to enter the Western markets. To avoid any delays, biotech companies need solid clinical development plans built on the latest regulatory guidance with intimate knowledge of the clinical trial landscape. This presentation will discuss how companies could design their clinical development plans to meet the Western regulators expectations. It will share insights on determining the extent of clinical data requirements, design of clinical studies, considerations on the study population/indication, endpoints, evaluation of risk of immunogenicity and designing global development programs. Further, the presentation will share insights on efficient operational delivery of the safety and efficacy studies and outline best practices for accessing and retaining patients in biosimilars clinical studies.
Biography

Charu Manaktala is an MD in Pediatric Medicine, the Senior Director, Strategic Drug Development (Asia) and Head of Asia Pacific Biosimilars Centre of Excellence at QuintilesIMS, Canada. She has over 20 years of work experience in the healthcare and pharmaceutical industry and has worked in all stages of clinical drug development from Phase-I through commercialization. Her experience spans a variety of disciplines including drug development, medical writing and pharmacovigilance. She has comprehensive experience in clinical development of pharmaceutical/biopharmaceutical products and advises biotechnology companies on region specific and/or global clinical strategies for the development of biopharmaceutical products with a special focus on biosimilars.

Email: [email protected]

Top